

Faculty

Chairs:

Dr William D Fisher

McGill University Health Centre
Montréal, Canada

Dr Juan V Llau

Hospital Clinico Universitario
Valencia, Spain

Speakers:

Dr Wolfgang Klauser

Endo-Klinik Hamburg
Hamburg, Germany

Dr Markus Michel

Münsingen Orthopaedic Centre
Münsingen, Switzerland

Dr Markus Quante

Klinikum Neustadt
Neustadt, Germany

Dr Juan V Llau

Hospital Clinico Universitario
Valencia, Spain

Sponsored by Bayer Schering Pharma AG

The marketing authorization for rivaroxaban may vary from country to country. In Spain, rivaroxaban is approved for the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery

© Bayer Schering Pharma AG 2010



BHC02289/0610
LES.GM.XAR.03.2010.0002

Cementing the Benefits


Oral anticoagulants in orthopaedic practice

Chaired by William D Fisher and Juan V Llau

Friday 4 June 2010, 13:15–14:30

Room N104, IFEMA Feria de Madrid, North Convention Centre, Madrid, Spain

A Satellite Symposium sponsored by Bayer Schering Pharma AG at the
11th Congress of the European Federation of National Associations of Orthopaedics and Traumatology
Madrid, Spain
2–5 June 2010



Chairmen's Welcome

Dear Colleagues,

We are delighted to invite you to attend a Satellite Symposium at the Congress of the European Federation of National Associations of Orthopaedics and Traumatology, which will focus on the new oral anticoagulants in orthopaedic practice.

Today the oral, direct Factor Xa inhibitor rivaroxaban is approved in more than 90 countries worldwide, including the EU and Canada, for the prevention of venous thromboembolism after elective hip or knee replacement surgery in adult patients. Clinical experience with rivaroxaban in this indication is growing rapidly, and this Symposium will provide a forum in which to explore some of the practical management questions relating to the clinical use of rivaroxaban.


Specialists from around Europe will outline their personal experiences with rivaroxaban in orthopaedic practice, including presentation of real-life case studies. They will also share with you their perspective on 'hot topics' of practical management such as optimal timing and duration of anticoagulant therapy. From an anaesthesiologist's perspective the important topics of concomitant pain management and timing of epidural catheter removal will also be discussed.

We hope that you will be able to join us for what promises to be a highly interesting, practical and interactive programme.

Kind regards,



William D Fisher



Juan V Llau

Cementing the Benefits

Oral anticoagulants in orthopaedic practice

Chaired by William D Fisher and Juan V Llau

Friday 4 June 2010, 13:15–14:30

Room N104, IFEMA Feria de Madrid, North Convention Centre, Madrid, Spain

A Satellite Symposium sponsored by Bayer Schering Pharma AG at the EFORT Annual Congress 2010, 2–5 June 2010

13:15 Welcome and introduction

William D Fisher, Canada

13:25 Perspectives from Germany: Practical implications of thromboprophylaxis after knee replacement surgery

Wolfgang Klauser, Germany

13:40 Perspectives from Switzerland: Clinical experience with rivaroxaban after minimally invasive hip replacement surgery

Markus Michel, Switzerland

13:55 The Stopwatch project: Practical implications for daily care

Markus Quante, Germany

14:10 Practical solutions to common clinical questions: An anaesthesiologist's perspective

Juan V Llau, Spain

14:25 Summary

William D Fisher, Canada and Juan V Llau, Spain

